Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Mental Health After Two Obesity Treatments

A six-month cohort compared psychological outcomes after bariatric surgery and incretin therapy, including tirzepatide and semaglutide.

Why we wrote this. Psychological change can be oversimplified as a direct drug effect. This cohort cannot establish that claim.

In this article (6 sections)
  1. How the cohort was designed
  2. Weight change differed between groups
  3. What changed on the 16 scales
  4. Adjustment changed the comparison
  5. What we do not yet know
  6. The careful takeaway

A prospective six-month cohort found improved psychiatric symptoms, psychological well-being and quality of life after either metabolic and bariatric surgery or incretin-based pharmacotherapy. The medicine group mostly received tirzepatide, with smaller numbers receiving semaglutide or liraglutide. Because treatment was not randomized, the study shows associations rather than proving that one treatment caused the psychological changes[1].

How the cohort was designed

The study included 207 adults with obesity. Ninety-seven underwent metabolic and bariatric surgery, while 110 received incretin-based pharmacotherapy. In the medicine group, 87 received tirzepatide, 19 semaglutide and four liraglutide[2]. Participants completed 16 psychiatric and quality-of-life scales before treatment and again at six months.

This was a prospective cohort, meaning the investigators assessed participants forward from baseline. It was not a randomized comparison. Treatment choice may have reflected clinical eligibility, patient preference, access and other factors that also relate to mental health or quality of life.

EMA identifies Mounjaro as an authorized tirzepatide medicine with specified indications and conditions of use[3]. The cohort paper evaluated outcomes after real clinical treatment. It did not test unlicensed products or establish that the same findings apply outside supervised care.

Weight change differed between groups

Mean weight loss at six months was 33.2 kilograms in the surgery group and 16.8 kilograms in the pharmacotherapy group. The reported standard deviations were 9.9 and 11.5 kilograms, respectively[1]. The larger average loss after surgery is central to interpreting the unadjusted psychological differences.

These averages do not predict an individual's response. They also do not create a direct efficacy ranking among the three medicines because the pharmacotherapy group pooled them and was dominated by tirzepatide. The abstract does not report separate psychological results for each medicine.

What changed on the 16 scales

Both groups improved significantly on all 16 psychiatric, well-being and quality-of-life scales. Reported effect-size correlations ranged from 0.28 to 0.84, and all p values were 0.02 or lower[2]. The public abstract does not list each scale's absolute baseline and follow-up score, so the clinical size of every change cannot be judged from the abstract alone.

In the pharmacotherapy group, improvement correlated with weight loss on every scale. Correlation magnitudes ranged from 0.20 to 0.45. After surgery, the investigators found no association between the amount of weight lost and scale improvement[1]. The authors suggest that less variable weight loss after surgery may help explain that contrast.

Correlation does not identify a mechanism. Weight change may accompany changes in mobility, sleep, social experience or health status. Treatment expectations and contact with clinical teams may also matter. The cohort cannot isolate a direct psychological action of incretin medicines from these linked changes.

Adjustment changed the comparison

Before adjustment, five of the 16 scales favored surgery. Those differences were no longer evident after the analysis adjusted for weight loss[2]. This suggests that greater weight loss accounted for the crude group advantage in those measures, within the assumptions of the statistical model.

Emotion-regulation difficulty was the one reported exception. Its group-by-time interaction coefficient was 3.3, with a 95% confidence interval from 0.7 to 5.9[1]. An interaction indicates that change over time differed between groups. The abstract does not provide enough scale detail here to convert the coefficient into a simple claim about how much better one treatment was.

Statistical adjustment can reduce measured imbalance, but it cannot recreate random assignment. It depends on correct modeling and on measured variables. Unmeasured differences between people choosing surgery and medicine may remain.

Sixteen scales also create a broad outcome set. The abstract reports improvement across all of them, but readers cannot see from the public record whether the analysis adjusted for repeated testing or how missing follow-up responses were handled. Those choices can affect confidence in individual scale results. The overall pattern is encouraging. It is not a diagnosis or a treatment recommendation.

The medicine group was unevenly distributed across products. With only four liraglutide recipients and 19 semaglutide recipients, this abstract cannot support product-level comparisons against the 87-person tirzepatide subgroup. Pooling is useful for the paper's treatment-modality question, but it limits molecule-specific conclusions.

What we do not yet know

Follow-up lasted six months, so the study does not establish whether psychological changes persist, strengthen or fade. It cannot compare the individual incretin medicines reliably because the smaller semaglutide and liraglutide groups were not presented separately. Nor can it show whether medication discontinuation changes the pattern.

The result should not be read as evidence that an obesity treatment replaces mental-health care. Anyone experiencing worsening mood, severe anxiety, self-harm thoughts or another acute psychiatric concern needs appropriate professional support. More detail on the medicines appears in our tirzepatide research overview.

The careful takeaway

Participants in both treatment groups reported broad improvement over six months. In the medicine group, larger weight loss was associated with larger psychological improvement. The design cannot establish a treatment-specific mental-health effect, and adjustment removed most crude differences favoring surgery. That makes the paper useful for describing a clinical cohort, not for choosing a treatment on psychological grounds alone.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did surgery improve mental health more than incretin therapy?

Five unadjusted scale comparisons favored surgery, but those differences disappeared after adjustment for weight loss. Treatment was not randomized.

Which incretin medicines were included?

The medicine group included 87 participants receiving tirzepatide, 19 receiving semaglutide and four receiving liraglutide.

Did the study prove a direct antidepressant effect?

No. It measured psychological changes alongside treatment and weight loss. The cohort design cannot isolate a direct drug effect or establish causation.

Sources

  1. [1]Acar MA et al. Psychiatric symptoms, psychological well-being and quality of life after metabolic and bariatric surgery versus incretin-based therapy in obesity. 2026. PMID 42994195Tier 1 · primary↩
  2. [2]Europe PMC indexed abstract record for PMID 42994195Tier 1 · primary↩
  3. [3]EMA medicine overview for Mounjaro (tirzepatide)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars